Medicare and Medicaid will cover Wegovy for its recently approved indication to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease and obesity.
The Centers for Medicare and Medicaid Services (CMS) has issued guidance that Medicare Part D plans can provide some coverage of Wegovy (semaglutide), but only if beneficiaries have an additional “medically accepted indication.”
But Wegovy or any other drug that receives FDA approval for chronic weight management alone would not be considered a Part D drug, according to a CMS spokesperson. “If this same drug also receives FDA approval to treat diabetes or reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight, then it would be considered a Part D drug for those specific uses only,” the spokesperson said.
Within Medicaid, states are now required to cover Wegovy to prevent cardiovascular disease in people with obesity. But states can also use utilization management and step therapy.
This was first reported by the Wall Street Journal but confirmed with CMS.
The CMS spokesperson said Medicare Part D specifically excludes certain drugs and uses such as “agents when used for anorexia, weight loss, and weight gain.” Since the beginning of the Part D program in 2006, all drugs when used for weight loss have been excluded from basic coverage.
CMS is clarifying that if those same drugs are approved for medically covered condition, they can be considered a Part D for that new use only.
Related: FDA Approves Additional Indication for Wegovy
The decision to provide some limited coverage was made after Wegovy received FDA approval earlier this month to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease and obesity. The approval is based on the SELECT cardiovascular outcomes trial, which demonstrated that Wegovy statistically significantly reduced the risk of MACE by 20% compared with placebo when added to standard of care.
Wegovy 2.4 mg, developed by Novo Nordisk, was approved first to treat obesity in adults in June 2021. It has a list price of $1,349.02 per package, which is a 28-day supply. Novo Nordisk also markets a lower-dose version of semaglutide as Ozempic to treat patients with diabetes. It is available in 0.5 mg, 1.0 mg and 2.0 mg doses. The list price of Ozempic 1.0 mg is $935.77 for one pen.
Additionally, Novo Nordisk announced that Ozempic 1.0 mg reduced kidney disease progression, major adverse cardiovascular events and death by 24%, according to topline results from the FLOW trial. The trial was stopped early on the recommendation from an independent data monitoring committee because an interim analysis found the study met the criteria for efficacy.
FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, as a result of a global settlement with Amgen, according to a company news release.
Read More
FDA Approves First Drug for Excess Hunger in Prader-Willi Syndrome
March 27th 2025Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi syndrome. The price is based on a patient’s weight, and the average patient in the clinical trials would have had an average annual cost of $466,200 for the first year.
Read More
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More